{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:36:40Z","timestamp":1793090200185,"version":"4.5.0"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105630","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:22:15Z","timestamp":1790688135000},"page":"105630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting the untargeted: Emerging targeted therapies in metastatic melanoma beyond BRAF\/MEK inhibitors"],"prefix":"10.1016","volume":"227","author":[{"given":"Marianna-Elisavet","family":"Dimitrakopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Theocharopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Katsandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Foteinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Stefanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Gkoufa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Tsoukalas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thalia","family":"Bousou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Anastasopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2620-4004","authenticated-orcid":false,"given":"Dimitrios C.","family":"Ziogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105630_bib1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2147\/OTT.S404648","article-title":"c-kit receptors as a therapeutic target in cancer: current insights","volume":"16","author":"Abdellateif","year":"2023","journal-title":"Onco Targets Ther."},{"issue":"36","key":"10.1016\/j.critrevonc.2026.105630_bib2","doi-asserted-by":"crossref","first-page":"17990","DOI":"10.1073\/pnas.1901323116","article-title":"Regulation of PRMT5-MDM4 axis is critical in the response to CDK4\/6 inhibitors in melanoma","volume":"116","author":"AbuHammad","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105630_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70251","article-title":"BRAF(V600E)-PROTAC versus inhibitors in melanoma cells: Deep transcriptomic characterization","volume":"15","author":"Alhassan","year":"2025","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105630_bib4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2326-6066.CIR-25-0744","article-title":"RAS(ON) multiselective inhibition drives antitumor immunity in preclinical models of NRAS-mutant melanoma","volume":"14","author":"Anastacio Da Costa Carvalho","year":"2026","journal-title":"Cancer Immunol. Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105630_bib5","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma.","volume":"161","author":"Anon","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105630_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105630_bib7","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1091\/mbc.12.11.3451","article-title":"Pmel17 initiates premelanosome morphogenesis within multivesicular bodies","volume":"12","author":"Berson","year":"2001","journal-title":"Mol. Biol. Cell."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105630_bib8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1158\/1535-7163.MCT-19-0183","article-title":"ERK inhibitor LY3214996 targets ERK pathway-driven cancers: a therapeutic approach toward precision medicine","volume":"19","author":"Bhagwat","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105630_bib9","article-title":"HERTHENA-PanTumor01: a global, multicohort, phase 2 trial of HER3-DXd in relapsed\/refractory metastatic solid tumors","volume":"42","author":"Bhatia","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105630_bib10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nm.4472","article-title":"Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF\/MEK inhibitors","volume":"24","author":"Boshuizen","year":"2018","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105630_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/PO-25-00886","article-title":"Molecular profiling and matched targeted therapy for patients with advanced melanoma: results from part 1 of the MatchMEL study","volume":"10","author":"Boutros","year":"2026","journal-title":"JCO Precis. Oncol."},{"issue":"56","key":"10.1016\/j.critrevonc.2026.105630_bib12","doi-asserted-by":"crossref","first-page":"95412","DOI":"10.18632\/oncotarget.20728","article-title":"EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma","volume":"8","author":"Capone","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105630_bib13","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1158\/2767-9764.CRC-23-0070","article-title":"PRMT5 inhibitors regulate DNA damage repair pathways in cancer cells and improve response to PARP inhibition and chemotherapies","volume":"3","author":"Carter","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105630_bib14","doi-asserted-by":"crossref","first-page":"S491","DOI":"10.1016\/j.annonc.2024.08.680","article-title":"613MO A phase I clinical trial evaluating exarafenib, a selective pan-RAF inhibitor in combination with binimetinib in NRAS-mutant (NRASMut) melanoma (Mel) & BRAF-altered solid tumors","volume":"35","author":"Cassier","year":"2024","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105630_bib15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrc4000","article-title":"MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road","volume":"15","author":"Caunt","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105630_bib16","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-019-0362-y","article-title":"Development of targeted protein degradation therapeutics","volume":"15","author":"Chamberlain","year":"2019","journal-title":"Nat. Chem. Biol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105630_bib17","first-page":"145","article-title":"Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody-drug conjugate","volume":"8","author":"Chang","year":"2025","journal-title":"Antib. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105630_bib18","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2490078","article-title":"Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody-drug conjugate","volume":"17","author":"Chang","year":"2025","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105630_bib19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/imm.13587","article-title":"MTAP deficiency contributes to immune landscape remodelling and tumour evasion","volume":"168","author":"Chang","year":"2023","journal-title":"Immunology"},{"issue":"29","key":"10.1016\/j.critrevonc.2026.105630_bib20","doi-asserted-by":"crossref","first-page":"24082","DOI":"10.1074\/jbc.M112.361485","article-title":"The melanosomal protein PMEL17 as a target for antibody drug conjugate therapy in melanoma","volume":"287","author":"Chen","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2026.105630_bib21","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fcell.2022.839997","article-title":"ERK5 signalling and resistance to ERK1\/2 pathway therapeutics: the path less travelled?","volume":"10","author":"Cook","year":"2022","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.critrevonc.2026.105630_bib22","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ejca.2022.06.015","article-title":"Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: initial experience from a compassionate use program in Italy","volume":"172","author":"Corti","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"6892","key":"10.1016\/j.critrevonc.2026.105630_bib23","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105630_bib24","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.22.02018","article-title":"Initial evidence for the efficacy of naporafenib in combination with trametinib in NRAS-mutant melanoma: results from the expansion arm of a phase Ib, open-label study","volume":"41","author":"de Braud","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105630_bib25","doi-asserted-by":"crossref","first-page":"17316","DOI":"10.1038\/s41598-024-68405-8","article-title":"Targeting PRMT5 enhances the radiosensitivity of tumor cells grown in vitro and in vivo","volume":"14","author":"Degorre","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105630_bib26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1172\/JCI82534","article-title":"Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth","volume":"126","author":"Dewaele","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2026.105630_bib27","doi-asserted-by":"crossref","first-page":"15262","DOI":"10.1038\/ncomms15262","article-title":"RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma","volume":"8","author":"Dorard","year":"2017","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105630_bib28","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1158\/1078-0432.CCR-24-0254","article-title":"Longitudinal genomic analysis to fine-tune targeted therapy: results of the phase II LOGIC 2 trial in patients with BRAFV600-mutant metastatic melanoma","volume":"31","author":"Dummer","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"Thesis 4","key":"10.1016\/j.critrevonc.2026.105630_bib29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1755-3768.2008.01182.x","article-title":"Receptors for the liver synthesized growth factors IGF-1 and HGF\/SF in uveal melanoma: intercorrelation and prognostic implications","volume":"86","author":"Economou","year":"2008","journal-title":"Acta Ophthalmol."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105630_bib30","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1158\/1078-0432.CCR-23-0416","article-title":"Clinical activity of combined telomerase vaccination and pembrolizumab in advanced melanoma: results from a phase I trial","volume":"29","author":"Ellingsen","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105630_bib31","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41568-021-00371-z","article-title":"Non-coding driver mutations in human cancer","volume":"21","author":"Elliott","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105630_bib32","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 Is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105630_bib33","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s43856-025-00932-5","article-title":"Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies","volume":"5","author":"Feichtenschlager","year":"2025","journal-title":"Commun. Med."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105630_bib34","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/0008-5472.CAN-26-1313","article-title":"Genetic drivers of sensitivity or resistance to RAS(ON) multiselective inhibitors in NRAS-mutated melanoma","volume":"86","author":"Foth","year":"2026","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105630_bib35","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.18632\/oncotarget.2270","article-title":"CDK4\/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer","volume":"5","author":"Franco","year":"2014","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105630_bib36","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41568-022-00490-1","article-title":"Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies","volume":"22","author":"Gao","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105630_bib37","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/nm.2863","article-title":"MDM4 is a key therapeutic target in cutaneous melanoma","volume":"18","author":"Gembarska","year":"2012","journal-title":"Nat. Med."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105630_bib38","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1158\/0008-5472.CAN-19-2416","article-title":"Extracellular-regulated protein kinase 5-mediated control of p21 expression promotes macrophage proliferation associated with tumor growth and metastasis","volume":"80","author":"Giurisato","year":"2020","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105630_bib39","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.ccell.2023.09.005","article-title":"Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance","volume":"41","author":"Gjuka","year":"2023","journal-title":"Cancer Cell."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105630_bib40","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","article-title":"CDK4\/6 inhibition in cancer: beyond cell cycle arrest","volume":"28","author":"Goel","year":"2018","journal-title":"Trends Cell. Biol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105630_bib41","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ccell.2017.11.006","article-title":"Genomic aberrations that activate D-type cyclins are associated with enhanced sensitivity to the CDK4 and CDK6 inhibitor abemaciclib","volume":"32","author":"Gong","year":"2017","journal-title":"Cancer Cell."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105630_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030466","article-title":"AXL receptor tyrosine kinase as a promising therapeutic target directing multiple aspects of cancer progression and metastasis","volume":"14","author":"Goyette","year":"2022","journal-title":"Cancers"},{"issue":"36","key":"10.1016\/j.critrevonc.2026.105630_bib43","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1038\/s41388-020-01405-w","article-title":"Targeting telomerase for cancer therapy","volume":"39","author":"Guterres","year":"2020","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105630_bib44","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/j.celrep.2018.08.002","article-title":"PRMT5 regulates DNA repair by controlling the alternative splicing of histone-modifying enzymes","volume":"24","author":"Hamard","year":"2018","journal-title":"Cell. Rep."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105630_bib45","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1158\/0008-5472.CAN-13-2923","article-title":"CDK4\/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers","volume":"74","author":"Heilmann","year":"2014","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105630_bib46","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ccell.2015.03.008","article-title":"Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin \u03b21\/FAK signaling","volume":"27","author":"Hirata","year":"2015","journal-title":"Cancer Cell."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105630_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100520","article-title":"Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma","volume":"7","author":"Janku","year":"2022","journal-title":"ESMO Open."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105630_bib48","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/ncb1802","article-title":"Arginine methylation regulates the p53 response","volume":"10","author":"Jansson","year":"2008","journal-title":"Nat. Cell. Biol."},{"key":"10.1016\/j.critrevonc.2026.105630_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2023.1098331","article-title":"E3 ligase ligand optimization of Clinical PROTACs","volume":"11","author":"Jiang","year":"2023","journal-title":"Front. Chem."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105630_bib50","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00008390-199310000-00006","article-title":"The progression associated antigen MUC18: a unique member of the immunoglobulin supergene family","volume":"3","author":"Johnson","year":"1993","journal-title":"Melanoma Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105630_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/cancers18030382","article-title":"Drug therapy for melanoma: current updates and future prospects","volume":"18","author":"Kato","year":"2026","journal-title":"Cancers"},{"issue":"551","key":"10.1016\/j.critrevonc.2026.105630_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5683","article-title":"PRMT5 control of cGAS\/STING and NLRC5 pathways defines melanoma response to antitumor immunity","volume":"12","author":"Kim","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105630_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113312","article-title":"A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)","volume":"193","author":"Kim","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"11_ement","key":"10.1016\/j.critrevonc.2026.105630_bib54","article-title":"Abstract PR02: LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4\/6\u2013 reactivating Rb in cancer","volume":"12","author":"Kim","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105630_bib55","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1158\/1078-0432.CCR-10-2307","article-title":"Expression of p16 and retinoblastoma determines response to CDK4\/6 inhibition in ovarian cancer","volume":"17","author":"Konecny","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105630_bib56","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.128199","article-title":"Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer","volume":"4","author":"Koopman","year":"2019","journal-title":"JCI Insight"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105630_bib57","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105630_bib58","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s13312-020-1736-7","article-title":"Antisense oligonucleotides: a unique treatment approach","volume":"57","author":"Krishnan","year":"2020","journal-title":"Indian. Pediatr."},{"key":"10.1016\/j.critrevonc.2026.105630_bib59","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.1002","article-title":"Results from the phase 1\/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)","volume":"40","author":"Krop","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105630_bib60","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1007\/s00018-016-2297-8","article-title":"Negative feedback regulation of the ERK1\/2 MAPK pathway","volume":"73","author":"Lake","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105630_bib61","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105630_bib62","doi-asserted-by":"crossref","first-page":"S1407","DOI":"10.1016\/j.annonc.2022.08.038","article-title":"LBA40 Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable\/metastatic, BRAF V600- or NRAS-mutant melanoma","volume":"33","author":"Lebbe","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105630_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.116162","article-title":"The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): a randomized open-label phase 2 study","volume":"233","author":"Lorigan","year":"2026","journal-title":"Eur. J. Cancer"},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105630_bib64","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1158\/1078-0432.CCR-20-4050","article-title":"Phase I-II open-label multicenter study of palbociclib + vemurafenib in BRAF (V600MUT) metastatic melanoma patients: uncovering CHEK2 as a major response mechanism","volume":"27","author":"Louveau","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105630_bib65","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2025.02.001","article-title":"FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma","volume":"43","author":"Lubrano","year":"2025","journal-title":"Cancer Cell."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105630_bib66","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-025-01753-8","article-title":"First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed\/refractory solid malignancies","volume":"18","author":"Mahadevan","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105630_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/cells10010142","article-title":"The WNT\/ROR pathway in cancer: from signaling to therapeutic intervention","volume":"10","author":"Menck","year":"2021","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105630_bib68","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up x2020","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105630_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/biom10101447","article-title":"Genetic alterations in the INK4a\/ARF locus: effects on melanoma development and progression","volume":"10","author":"Ming","year":"2020","journal-title":"Biomolecules"},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105630_bib70","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2217\/fon-2023-0602","article-title":"HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI","volume":"20","author":"Mok","year":"2024","journal-title":"Future Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105630_bib71","article-title":"A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM)","volume":"41","author":"Monga","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105630_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/life11101074","article-title":"The structure and functions of PRMT5 in human diseases","volume":"11","author":"Motolani","year":"2021","journal-title":"Life"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105630_bib73","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1158\/1535-7163.MCT-20-1126","article-title":"Targeting CDK4\/6 represents a therapeutic vulnerability in acquired BRAF\/MEK inhibitor-resistant melanoma","volume":"20","author":"Nassar","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105630_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074710","article-title":"PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1","volume":"8","author":"Nicholas","year":"2013","journal-title":"PLOS One"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105630_bib75","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/sj.embor.7400755","article-title":"MAPK signalling: ERK5 versus ERK1\/2","volume":"7","author":"Nishimoto","year":"2006","journal-title":"EMBO Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105630_bib76","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1535370220959657","article-title":"Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database","volume":"246","author":"Owsley","year":"2021","journal-title":"Exp. Biol. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105630_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13051115","article-title":"Resistance to molecularly targeted therapies in melanoma","volume":"13","author":"Patel","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105630_bib78","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1200\/JCO.23.00205","article-title":"Targeting NRAS mutations in advanced melanoma","volume":"41","author":"Phadke","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105630_bib79","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.bbamcr.2010.12.012","article-title":"The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation","volume":"1813","author":"Plotnikov","year":"2011","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Cell Res."},{"key":"10.1016\/j.critrevonc.2026.105630_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102443","article-title":"53O Results from a phase II part I trial of mecbotamab vedotin (BA3011), a CAB-AXL-ADC, in patients with advanced refractory sarcoma","volume":"9","author":"Pollack","year":"2024","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105630_bib81","doi-asserted-by":"crossref","first-page":"S534","DOI":"10.1016\/j.annonc.2024.08.2161","article-title":"690TiP HERTHENA-PanTumor01: a global phase II trial of HER3-DXd in metastatic solid tumors","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105630_bib82","doi-asserted-by":"crossref","first-page":"17005","DOI":"10.1038\/cddiscovery.2017.5","article-title":"Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM\/MUC18\/MelCAM\/CD146","volume":"3","author":"Rapanotti","year":"2017","journal-title":"Cell. Death Discov."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105630_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212416","article-title":"MCAM\/MUC18\/CD146 as a multifaceted warning marker of melanoma progression in liquid biopsy","volume":"22","author":"Rapanotti","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105630_bib84","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-08-0186","article-title":"HER3 is a determinant for poor prognosis in melanoma","volume":"14","author":"Reschke","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"46","key":"10.1016\/j.critrevonc.2026.105630_bib85","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1038\/s41388-025-03603-w","article-title":"A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibition","volume":"44","author":"Riordan","year":"2025","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105630_bib86","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105630_bib87","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1158\/2767-9764.CRC-25-0359","article-title":"Phase I\/II study of AXL-specific antibody\u2013drug conjugate enapotamab vedotin in patients with advanced solid tumors","volume":"5","author":"Rohrberg","year":"2025","journal-title":"Cancer Res. Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105630_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104300","article-title":"A phase I, first-in-human trial of KO-947, an ERK1\/2 inhibitor, in patients with advanced solid tumors","volume":"10","author":"Schram","year":"2025","journal-title":"ESMO Open."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105630_bib89","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1158\/1078-0432.CCR-21-3872","article-title":"Phase Ib\/II trial of ribociclib in combination with binimetinib in patients with NRAS-mutant melanoma","volume":"28","author":"Schuler","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105630_bib90","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0092-8674(00)81902-9","article-title":"Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a","volume":"88","author":"Serrano","year":"1997","journal-title":"Cell"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105630_bib91","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1158\/0008-5472.CAN-23-1356","article-title":"A cell surface-binding antibody atlas nominates a MUC18-directed antibody-drug conjugate for targeting melanoma","volume":"83","author":"Shi","year":"2023","journal-title":"Cancer Res."},{"issue":"6_ement","key":"10.1016\/j.critrevonc.2026.105630_bib92","article-title":"Abstract 739: AMT-253, a first-in-class MUC18-targeting antibody-drug conjugate, for the treatment of MUC18-positive solid tumors","volume":"84","author":"Shi","year":"2024","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105630_bib93","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pathol.2023.03.007","article-title":"Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma","volume":"55","author":"Shteinman","year":"2023","journal-title":"Pathology"},{"key":"10.1016\/j.critrevonc.2026.105630_bib94","doi-asserted-by":"crossref","first-page":"v159","DOI":"10.1093\/annonc\/mdz244","article-title":"METEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours","volume":"30","author":"Siu","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105630_bib95","article-title":"Protein arginine methyltransferase 5 as a novel therapeutic target in solid tumors","author":"Song","year":"2025","journal-title":"Genes. & Dis."},{"issue":"15_","key":"10.1016\/j.critrevonc.2026.105630_bib96","article-title":"A phase 1b\/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity.","volume":"32","author":"Sosman","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105630_bib97","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1093\/emboj\/17.17.5001","article-title":"The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2","volume":"17","author":"Stott","year":"1998","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105630_bib98","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","article-title":"First-in-class ERK1\/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study","volume":"8","author":"Sullivan","year":"2018","journal-title":"Cancer Discov."},{"issue":"50","key":"10.1016\/j.critrevonc.2026.105630_bib99","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/s41388-025-03641-4","article-title":"A selective RPL15 PROTAC degrader enhances anti-PD-1 immunotherapy in a murine melanoma tumor model","volume":"44","author":"Takahashi","year":"2025","journal-title":"Oncogene"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105630_bib100","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1038\/onc.2012.288","article-title":"Downregulation of splicing factor SRSF3 induces p53\u03b2, an alternatively spliced isoform of p53 that promotes cellular senescence","volume":"32","author":"Tang","year":"2013","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105630_bib101","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13046-023-02726-w","article-title":"AXL in cancer: a modulator of drug resistance and therapeutic target","volume":"42","author":"Tang","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105630_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116995","article-title":"Dual-payload antibody\u2013drug conjugates: Taking a dual shot","volume":"281","author":"Tao","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105630_bib103","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1158\/1078-0432.CCR-13-2846","article-title":"Semi-mechanistic pharmacokinetic\/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4\/6 inhibitor, in mice bearing human tumor xenografts","volume":"20","author":"Tate","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105630_bib104","doi-asserted-by":"crossref","first-page":"iv374","DOI":"10.1093\/annonc\/mdu344.2","article-title":"Phase Ib\/Ii study of Lee011 (Cdk4\/6 Inhibitor) and Lgx818 (Braf Inhibitor) in Braf-Mutant Melanoma","volume":"25","author":"Taylor","year":"2014","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105630_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9101111","article-title":"Antibody-drug conjugates: functional principles and applications in oncology and beyond","volume":"9","author":"Theocharopoulos","year":"2021","journal-title":"Vaccines"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105630_bib106","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0749.2005.00269.x","article-title":"The Silver locus product Pmel17\/gp100\/Silv\/ME20: controversial in name and in function","volume":"18","author":"Theos","year":"2005","journal-title":"Pigment. Cell. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105630_bib107","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/pcmr.12107","article-title":"Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells","volume":"26","author":"Todd","year":"2013","journal-title":"Pigment. Cell. Melanoma Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105630_bib108","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/cup.13689","article-title":"Germline mutations predisposing to melanoma","volume":"47","author":"Toussi","year":"2020","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105630_bib109","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","article-title":"RAF-MEK-ERK pathway in cancer evolution and treatment","volume":"85","author":"Ullah","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105630_bib110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13046-025-03635-w","article-title":"PROTAC-mediated degradation of Bcl-xL potentiates target therapy in preclinical melanoma models","volume":"45","author":"Valentini","year":"2026","journal-title":"J. Exp. & Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105630_bib111","doi-asserted-by":"crossref","first-page":"S492","DOI":"10.1016\/j.annonc.2024.08.681","article-title":"614MO Type II RAF inhibitor tovorafenib in recurrent\/refractory (R\/R) melanoma or other solid tumors with RAF fusions and\/or RAF1 amplification","volume":"35","author":"Vieito","year":"2024","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105630_bib112","doi-asserted-by":"crossref","DOI":"10.1093\/jleuko\/qiae141","article-title":"Receptor tyrosine kinase-like orphan receptor serves as a potential target in cancer immunotherapy","volume":"117","author":"Wang","year":"2025","journal-title":"J. Leukoc. Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105630_bib113","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231519","article-title":"PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy","volume":"221","author":"Wang","year":"2024","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105630_bib114","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/bjd\/ljaf178","article-title":"Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic","volume":"193","author":"Wang","year":"2025","journal-title":"Br. J. Dermatol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105630_bib115","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1158\/1535-7163.MCT-14-0257","article-title":"The CDK4\/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation","volume":"13","author":"Yadav","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105630_bib116","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/pcmr.12228","article-title":"Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4\/6 inhibitor PD0332991 in melanoma cell lines","volume":"27","author":"Young","year":"2014","journal-title":"Pigment. Cell. & Melanoma Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105630_bib117","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3892\/ol.2022.13613","article-title":"Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma","volume":"25","author":"Zablocka","year":"2023","journal-title":"Oncol. Lett."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105630_bib118","doi-asserted-by":"crossref","first-page":"8407","DOI":"10.1021\/acs.jmedchem.3c00250","article-title":"Targeting arginine methyltransferase PRMT5 for cancer therapy: updated progress and novel strategies","volume":"66","author":"Zheng","year":"2023","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105630_bib119","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102718","article-title":"Beyond CTLA-4 and PD-1 inhibition: novel immune checkpoint molecules for melanoma treatment","volume":"15","author":"Ziogas","year":"2023","journal-title":"Cancers"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:49:01Z","timestamp":1793087341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826005172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":119,"alternative-id":["S1040842826005172"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105630","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the untargeted: Emerging targeted therapies in metastatic melanoma beyond BRAF\/MEK inhibitors","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105630","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105630"}}